Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan vs dobutamine in acute ischemic heart failure
ChiCTR2200059855Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of levosimendan in Acute Heart Failure (AHF), coronary arteriosclerosis and Ischemic congestive heart failure (ICM-HF) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Natriuretic peptide level. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
levosimendan
03
Conditions
Acute Heart Failure (AHF)coronary arteriosclerosisIschemic congestive heart failure (ICM-HF)
Beyond the preview
Go deeper on ChiCTR2200059855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059855.